Cytokeratin 19 Rekombinanter Antikörper

Cytokeratin 19 Rekombinant Antikörper für WB, IHC, IF/ICC, IF-P, FC (Intra), Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, IF/ICC, IF-P, FC (Intra), Indirect ELISA

Konjugation

Unkonjugiert

CloneNo.

250894B1

Kat-Nr. : 86250-1-PBS

Synonyme

CK 19, CK19, KRT19, CK-19, Cytokeratin,Keratin



Geprüfte Anwendungen

Produktinformation

86250-1-PBS bindet in WB, IHC, IF/ICC, IF-P, FC (Intra), Indirect ELISA Cytokeratin 19 und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Kaninchen / IgG
Klonalität Rekombinant
Typ Antikörper
Immunogen Peptid
Vollständiger Name keratin 19
Berechnetes Molekulargewicht 44 kDa
Beobachtetes Molekulargewicht44 kDa
GenBank-ZugangsnummerBC002539
Gene symbol Cytokeratin 19
Gene ID (NCBI) 3880
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Protein-A-Reinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Cytokeratin 19 (CK19 or KRT19) is a type I (acidic) cytokeratin. It is an intermediate filament protein providing structural rigidity and multipurpose scaffolds in epithelial cells. CK19 is often overexpressed in various cancers (e.g., hepatocellular carcinoma [HCC], pancreatic adenocarcinoma, lung cancer) and serves as a biomarker for hepatic progenitor cells (HPCs) associated with poor prognosis in HCC patients . Additionally, CK19 expression is common in pancreatic and gastrointestinal adenocarcinomasand has been studied as a potential diagnostic and prognostic marker for pancreatic neuroendocrine tumors (PNETs), where positive CK19 expression correlates with poor prognosis. Serum CK19 fragments (e.g., CYFRA 21-1, CK19-2G2) have been investigated as tumor markers for lung and breast cancer, with preoperative levels associated with metastasis and survival.